UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 27, 2008
Biogen Idec Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| |
|
|
0-19311
(Commission File Number)
|
|
33-0112644
(IRS Employer Identification No.) |
| |
|
|
14 Cambridge Center, Cambridge, Massachusetts
(Address of Principal Executive Offices)
|
|
02142
(Zip Code) |
(617) 679-2000
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))x
TABLE OF CONTENTS
Item 8.01. Other Events.
As previously disclosed, clinically significant liver injury has been reported in patients
treated with TYSABRI in the post-marketing setting. Biogen Idec Inc. (the “Registrant”) and its
TYSABRI collaboration partner, Elan Corporation plc (“Elan”) have issued a letter to healthcare
professionals describing these risks. A copy of the letter was posted
today on the U.S. Food and Drug Administration’s website and is attached as exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
Exhibit 99.1
|
|
Dear Healthcare Professional letter, dated February 2008, issued by the Registrant and Elan. |
-2-